Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
allogeneicmedical
Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.
gamma delta T cellmedical
A gamma delta T cell is a type of white blood cell that acts like a specialized security guard in the immune system, detecting and responding to infected or damaged cells in ways that differ from the more common immune cells. Investors track them because they are targets for experimental therapies, diagnostics and biomarkers in cancer and infectious disease: advances or setbacks in this area can affect the value of biotech companies and drug pipelines.
autoimmune diseasesmedical
Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs, causing chronic inflammation and damage—think of the immune system as a home security system that wrongly targets the house instead of intruders. Investors care because these illnesses create sustained demand for diagnostics, long-term treatments and specialty drugs, influence regulatory scrutiny and healthcare costs, and can shape the commercial outlook for biotech and pharmaceutical investments.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York.
Details of the event are as follows:
Date: Thursday, February 12, 2026
Time: 2:00p.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
